Astec Lifesciences Ltd

- The company has not explicitly mentioned any current or future fundraising plans through debt or equity in the provided transcript. - However, Ashok Hiremath indicated that recent evaluations suggest the planned investment figure (capex) may go up. - They are prepared to be more aggressive with investment plans in the future, which may imply potential future capital raising. - Currently, the company is borrowing at very low rates (4.1%) and leveraging working capital efficiently to improve profitability. - The planned capex is Rs.150 Crore for the current year and Rs.300-350 Crore over a 2-3 year window, with possibility of an upward revision. - No mention was made of any specific equity raising or debt issuance underway or planned.

- Capex plan for FY2022 is on track with an expected spend of Rs.150 Crore. - Investments include completion of the new herbicide facility and ongoing construction of a new fungicide plant. - A new state-of-the-art R&D center is under construction, expected to be completed by the end of FY2023; currently, additional R&D capacities have been hired externally. - Future capex estimates over a 2-3 year window are expected to be in the Rs.300-350 Crore range, with potential to increase as per recent evaluations. - The company plans to be aggressive with capital investments to expand product portfolios and capacity. - Modifications are being planned at the Mahad facility to mitigate flooding risk due to climate change effects.

- Astec LifeSciences expects annualized sales growth of 15%-20% for FY2022. - Volume growth in H1 FY2022 was about 11%. - Enterprise sales value growth is targeted at 20%-25% this year, driven by 10%-15% volume growth. - CMO business is projected to grow at a compounded annual rate of 50% over the next three years. - CMO contribution is expected to rise gradually, with herbicide plant ramp-up increasing CMO capacity utilization from 30% this year to higher next year. - New product introductions: 4 CMO products and 1 enterprise product this year; 2 more enterprise products expected in FY2023. - Full utilization of the herbicide plant expected to reach 100% by the third year, currently at 30%-35% utilization. - Future growth also supported by backward integration and new fungicide plant investments. - Pricing improvements and better realizations expected to aid revenue growth despite some short-term production losses.

- Astec LifeSciences targets annualized revenue growth of 15%-20% as a general guidance. - EBITDA margins expected to improve from about 22% to 24% over coming years due to higher CMO business contribution, which commands ~5% better margins than enterprise sales. - The company anticipates a 50% growth in CMO business in FY2023 as new herbicide and fungicide products ramp up. - Enterprise business volume growth expected at 10%-15% with 20%-25% value growth in the current year. - Pricing pressures on key products are easing, with improved realizations expected, particularly in H2 FY2022. - Backward integration and price hikes are expected to contribute positively to margins going forward. - New product introductions: 4 CMO products plus 1 enterprise product this year, and 2 enterprise products (triazole fungicides) expected commercially by Q4 FY2023. - Capex planned at Rs.150 crore this year, potentially increasing to support growth initiatives.

- As of the call dated October 28, 2021, specific details about the current order book or pending orders were not directly disclosed. - Ashok Hiremath mentioned variability in Contract Manufacturing Organization (CMO) business depending on campaign-wise production with orders varying year-to-year. - There was mention of around Rs.29.5 Crore of revenue deferred from Q2 to Q3 due to shipment delays. - The CMO business experienced a lower contribution in H1 FY2022 but is expected to grow significantly (about 50% CAGR) over the next three years. - The herbicide plant started production in August and is on track to reach 30%-35% capacity utilization in the first year, progressing towards full capacity by the third year. - The company is working on several new products (4 CMO and 1 enterprise in the current year, and 2 more enterprise products next year) which indicate order inflow in the near term. - Management expressed aspirations to increase the CMO business proportion to around 40% in coming years.